Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S has announced a reduction in its B share capital following the Annual General Meeting decision on March 21, 2024. The Danish healthcare giant, known for its commitment to defeating serious chronic diseases, confirmed the cancellation of 45 million B shares and assured that this reduction will not impact its ongoing share repurchase program. With a strong global presence, the company continues to employ over 63,000 people and maintains its product availability in approximately 170 countries.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
